Idiopathic juxtafoveal retinal telangiectasis with co-existent diabetic retinopathy

Session Details

Session Title: Free Paper Session 16: Vascular Diseases & Diabetic Retinopathy IV

Session Date/Time: Friday 08/09/2017 | 16:30-18:00

Paper Time: 17:36

Venue: Room 114

First Author: : M.Jhingan INDIA

Co Author(s): :    J. Chhablani                             

Abstract Details


To report natural history of idiopathic juxtafoveal retinal telangiectasias (IJRT) treated and untreated in coexistence with diabetic retinopathy (DR)


L.V. Prasad Eye Institute, Hyderabad


A retrospective chart review was done for all eyes with IJRT and DR with a minimum 2 years follow up. Eyes with other retinal disorders and poor quality imaging were excluded. Data collected included demographics, presenting visual acuity, systemic evaluation, treatments done, duration of follow up, and final visual outcomes. These data-sets were then analysed statistically.


Out of 951 patients with IJRT, 277 patients had diabetes. Out of 277 patients, 44 eyes of 22 patients had IJRT coexisting with DR. 28 eyes of 14 patients were included in this study. All cases of IJRT were bilateral with a preponderance of women (71.42%). Mean follow up was 84.5 ± 59.3 months with a mean random blood sugar level of 135.41 ± 45.47mg% at presentation. Hypertension was seen in 50% of the patients. All cases with stage V IJRT were hypertensive. 25 (89.28%) eyes presented with mild NPDR. Two (7.14%) eyes progressed in their DR staging from baseline. Stage III IJRT were noted in 11 (39.28)% eyes at baseline. No patient progressed to stage V IJRT during follow up. Mean presenting logMAR BCVA was 0.214 ± 0.227 (20/32 Snellen’s equivalent) which dropped to 0.399 ± 0.301 (20/50 Snellen’s equivalent) at last visit (p=0.0005). Diabetic macular edema (DME) was not noted in any patient over follow up.


7.94% of eyes with IJRT in diabetic patients had coexistence DR. IJRT leads to slowly progressive visual loss irrespective of the presence of DR. IJRT may have a protective role against the occurrence of DME and progression of DR.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy